Inflammatory bowel disease (IBD) is a complex genetic disease that is instigated and
amplified by the confluence of multiple genetic and environmental variables that perturb the …

Perturbations in the intestinal microbiome are implicated in inflammatory bowel disease
(IBD). Studies of treatment-naive patients have identified microbial taxa associated with …

For decades, variability in clinical efficacy of the widely used inflammatory bowel disease
(IBD) drug 5-aminosalicylic acid (5-ASA) has been attributed, in part, to its acetylation and …

Persistent colonization and outgrowth of potentially pathogenic organisms in the intestine
can result from long-term antibiotic use or inflammatory conditions, and may perpetuate …

Background & Aims Biomarkers are used frequently for noninvasive monitoring and
treatment decision making in the management of patients with ulcerative colitis (UC). This …

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's
disease (CD), is characterized by relapse and remission alternately. It remains a great …

Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …

Background & Aims Altered interactions between the mucosal immune system and intestinal
microbiota contribute to pathogenesis of inflammatory bowel diseases (IBD). It is not clear …

Understanding the role of the microbiome in inflammatory diseases requires the
identification of microbial effector molecules. We established an approach to link disease …

Inflammatory bowel diseases (IBDs) are chronic problems of gastrointestinal tract (GIT) with
poorly understood aetiology. Patients with any of the two common entities, Crohn's disease …